Edward is a partner at Amadeus Capital Partners, focused on deep-tech investments in the areas of health-tech, food & ag-tech and industry 4.0.
Edward was previously at M Ventures, the €400 million AUM corporate VC-arm of Merck KGaA, where he was responsible for health-tech, frontier-tech and sustainability investments. Edward led, among others, the investments in Akili Interactive Labs (the first-ever FDA-approved prescription video-game); Wiliot (battery-free Bluetooth tag with infinite lifetime, enabling a true connected-everything) and Sonde Health (voice-analysis platform for health and wellness inferences for use on self-owned devices).
Prior to M Ventures, Edward was in the Life Sciences securities team at Kempen & Co, a pan-European merchant bank, covering listed small- and mid-cap Life Sciences equities. He started his career within the biopharma investment team of M Ventures.
Edward holds an MSc in Biopharmaceutical Sciences from Leiden University, The Netherlands, with a specialisation in pharmacology.
Francesca Domenech Wuttke
Francesca Domenech Wuttke, Ph.D. is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end companywide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall. Dr. Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 25 years of clinical, research, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia. Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr. Wuttke led Almirall´s Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Before that Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organization as well as managing the strategy and commercialization for the existing portfolio of cell therapy assets. Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
Lee is managing partner at 7wireVentures, a Chicago-based investment firm he co-founded over a decade ago. He also served as Chief Financial Officer of Livongo Health [NASDAQ:LVGO] until November 2020. He serves on the boards of Senior Connect [NASDAQ:SNRHU}, a special purpose acquisition company focused on the aging space, and Clover Health [NASDAQ:CLOV]. He is also active with and serves on the board of many of the 7wire portfolio companies.
Prior to stepping in as CFO of Livongo and leading its 2019 IPO, Lee served on the board of the company since its launch, chairing the audit committee and as a member of its compensation committee. During his tenure as CFO, Livongo also had a successful secondary offering, raised $550M in convertible debt and entered into a merger agreement at the highest valuation of any healthcare technology deal, based on revenue multiples.
Lee served as president of Allscripts [NASDAQ:MDRX] from 2001 through 2012. He is a co-founder and board member of The World Innovation Network, the University of Chicago Innovation Fund Advisory Committee, and the Samsung Digital Health Advisory Board. Based on his industry experience, he is a frequent speaker at industry conferences and a published contributor to the Forbes Business Council.
For the past 4 years, Lee has been a member of the National Board of Directors of the American Heart Association, where he chairs the audit committee and serves on the business operations committee. Lee earned his JD degree from The University of Chicago Law School and a BS in Accounting from The University of Illinois Urbana-Champaign.
Mussaad Al Razouki
Dr Razouki is the current chief business development officer of Kuwait Life Sciences Company (KLSC) where he is responsible for identifying new business opportunities for all KLSC subsidiary companies as well as sourcing investment opportunities for KLSC’s US$50 million investment fund. Dr Razouki is a regional thought leader within the Middle East life sciences industry having shifted from clinical practice and research to the management and financing of healthcare systems. He is also a Board member of the Arab Company for Drug Industries and Medical Applications (ACDIMA).
Ittai currently serves on the Board of Directors of DouxMatok, EarlySense, Medisafe, Clew Medical, Tscan, Vertos Medical and Visby Medical. He also serves as the Chairman of the Board at EarlySense.
His investments focus on Digital Health, Health-IT and MedTech, and he brings with him over 15 years of experience in Venture Capital as well as 20 years of experience in operations and management roles.
Before joining Pitango, Ittai headed Corporate Development at Nektar Therapeutics (NASDAQ: NKTR), served as Executive Vice President roles at IDGene Pharmaceuticals and IDEXX Laboratories (NASDAQ: IDXX).
Ittai holds a B.Sc. in Chemical Engineering and Biotechnology from Ben-Gurion University, and an MBA from the MIT Sloan School of Management.